Xilio Therapeutics
31 hedge funds and large institutions have $13.7M invested in Xilio Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 30 → 31 (+1)
2% more capital invested
Capital invested by funds: $13.4M → $13.7M (+$299K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.43% less ownership
Funds ownership: 3.23% → 2.81% (-0.43%)
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
26
ADAR1 Capital Management
Austin,
Texas
| $1.42K | +$1.68K | +107 | New |
|
|
KFI
27
Key Financial Inc
West Chester,
Pennsylvania
| $786 | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $656 | +$767 | +49 | New |
|
29
UBS Group
Zurich,
Switzerland
| $191 | – | – | – |
|
30
JP Morgan Chase
New York
| $56 | -$3.01K | -192 | -98% |
|
31
Qube Research & Technologies (QRT)
London,
United Kingdom
| $4 | – | – | – |
|
|
AVLSA
32
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
| – | -$1.07M | -70,922 | Closed |
|
|
PI
33
PFG Investments
Woodbury,
New York
| – | -$32.4K | -2,143 | Closed |
|
|
PCM
34
Prelude Capital Management
New York
| – | -$31.9K | -2,107 | Closed |
|
|
FIA
35
FNY Investment Advisers
New York
| – | -$29 | -1,964 | Closed |
|
|
STA
36
Summit Trail Advisors
New York
| – | -$17.3K | -1,143 | Closed |
|
37
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$188 | -12 | -32% |
|
38
Wells Fargo
San Francisco,
California
| – | -$117 | -8 | Closed |
|
XLO Hedge Fund Activity: Q2 2024 in Review
31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2024, worth a combined $13.7M — up 2.2% from $13.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new XLO positions and 6 closed out — a net gain of 1 holder — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Rock Springs Capital Management, adding an estimated $1.75M. The largest seller was Atlas Venture Life Science Advisors, exiting entirely with an estimated $1.07M sold.
- 31 institutional investors held Xilio Therapeutics (XLO) as of Q2 2024, up from 30 in Q1 2024.
- Funds reported $13.7M of Xilio Therapeutics stock for Q2 2024, up 2.2% quarter-over-quarter.
- 7 funds opened new Xilio Therapeutics positions in Q2 2024 and 6 closed out, a net change of +1 holder.
- The largest Xilio Therapeutics buyer in Q2 2024 was Rock Springs Capital Management, an estimated $1.75M added.
- The largest Xilio Therapeutics seller in Q2 2024 was Atlas Venture Life Science Advisors, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2024.